First Author: B.Kambo ALBANIA
Back to previous
To evaluate the anatomic and visual acuity outcomes of intravitreal aflibercept 2 mg in cases of diabetic macular edema (DME)
Laser Eye Clinic, Tirana, Albania
In this retrospective interventional case series, DME patients with macular fluid were treated with IVI aflibercept 2.0 mg. Collected data includes details of prior treatments, best available visual acuity, central subfield thickness (CST), and the area of thickest edema on registered SD-OCT before and after aflibercept IVI.
A total of 24 eyes with persistent DME were included. All eyes had macular fluid in OCT. At 1 month after the first aflibercept IVI, 75% (18/24 eyes) showed anatomic improvement. On average, CST decreased from 441 to 332 microns after one aflibercept IVI. When measuring the thickest point in the macula on registered SD-OCT, the thickness decreased from 536 to 442 microns after one aflibercept IVI. All eyes followed over multiple aflibercept injections showed further improvement . Visual acuity improved in 19 of 24 eyes one month after the first aflibercept IVI. Treatment was well tolerated with no adverse events.
A majority of DME cases with macular fluid on SD-OCT showed a positive anatomic response to aflibercept 2.0 mg. IVI aflibercept appears to be anatomically beneficial and may improve the visual acuity in cases of DME.